Fate Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 46 U.S.-traded ETFs. FATE has around 7.2M shares in the U.S. ETF market. The largest ETF holder of FATE is the SPDR S&P Biotech ETF (XBI), with approximately 1.86M shares. Investors may also find of interest that the ETF with the largest allocation to FATE stock is Loncar Cancer Immunotherapy ETF (CNCR), with a portfolio weight of 3.80%. On average, U.S. ETFs allocate 0.47% of FATE to their portfolios.
Additionally, FATE is a favorite stock for Vanilla and Active ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with FATE as a holding is the ARK Genomic Revolution ETF (ARKG), with a return of 68.27%.